SECsense Logo

Protagonist Therapeutics, Inc. 8-K Report: Key Insights & Investor Updates

$PTGX
Form 8-K
Filed on: 2025-02-21
Source
Protagonist Therapeutics, Inc. 8-K Report: Key Insights & Investor Updates

Here are the key insights extracted from the financial report section provided:

  1. Entity Information:
  • Company Name: Protagonist Therapeutics, Inc.
  • CIK Code: 0001377121
  • Address: 7707 Gateway Blvd. Suite 140, Newark, CA 94560-1160
  • Phone Number: 510-474-0170
  • State of Incorporation: Delaware (indicated by "DE")
  • SEC File Number: 001-37852
  • EIN: 98-0505495
  1. Filing Information:
  • Filing Type: 8-K (a report used to announce major events that shareholders should know about)
  • Filing Date: February 21, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.00001
  • Ticker Symbol: PTGX
  • Exchange: NASDAQ
  1. Reporting Period:
  • As of Date: February 21, 2025
  1. Units of Measure:
  • Currency: USD (U.S. Dollar)
  • Shares: Document indicates a unit of measure in shares.

Summary: The report is an 8-K filing by Protagonist Therapeutics, Inc., submitted on February 21, 2025, regarding events that may be significant to investors. The company is based in Newark, California, and is listed on NASDAQ under the ticker symbol PTGX, with a very low par value for its common stock. The filing is structured in XBRL format, which is common for SEC filings to facilitate data analysis.

This information is relevant for investors, analysts, and stakeholders interested in the company's activities and financial status as of the specified date.